Skip to content.

Companies

Acquired by Apple

Acquired by Apple

Acquired by Capital D

Acquired by Capital D

Acquired by Oracle

Acquired by Oracle

Acquired by Siemens

Acquired by Siemens

Acquired by ERT Clinical

Acquired by ERT Clinical

IPO: AREC

IPO: AREC

IPO: ORTX

IPO: FRLN

IPO: ACHL

IPO: MGTX

Acquired by Facebook

IPO: BKNG

  • UCL Tech Fund investments
  • Established
    2016
    In collaboration with UCL Business
  • Total investment
    > $2bn
    Over $2bn of follow on funding for portfolio
  • Public offerings
    4 IPOs
    Four NASDAQ IPOs since 2018

Featured investments

Carbon Re raises £4.2m seed funding to tackle gigatonnes of emissions

Read the article >
Bloomsbury GTX launches with Seed financing of £5m to develop the promise of gene therapy

Bloomsbury GTX raises £5m Seed funding to develop curative gene therapy treatments

Read the article >

Bramble Energy among 23 deeptech startups primed to take off | Business Insider

Bramble Energy | Business Insider

Read the article >
Companies
  • Achilles Therapeutics
    Biopharmaceutical company developing precision T cell therapies
    Sector: UCL Tech Fund
    Status: Nasdaq IPO
  • Gene therapy company developing disease-transformative medicines for ciliopathies
    Sector: UCL Tech Fund
    Status: Early Stage
  • Bloomsbury AI
    Enabling everyone to easily create their own question-answering system
    Sector: UCL Tech Fund
    Status: Exited
  • Biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases
    Sector: UCL Tech Fund
    Status: Early Stage
  • Fuel cell company on a mission to help the world achieve net zero
    Sector: UCL Tech Fund
    Status: Growth
  • Climate tech startup utilising AI to achieve operational efficiency in energy intensive industries
    Sector: UCL Tech Fund
    Status: Early Stage
  • Transforming interventional cardiology with optical-fibre based sensors
    Sector: UCL Tech Fund
    Status: Early Stage
  • Immuno-oncology company targeting cancer with the IgE class of antibodies
    Sector: UCL Tech Fund
    Status: Early Stage
  • Freeline Therapeutics
    Biopharmaceutical company focused on the development of liver-directed gene therapies
    Sector: UCL Tech Fund
    Status: Nasdaq IPO
  • Synthetic data platform
    Sector: UCL Tech Fund
    Status: Early Stage
  • DevOps tool that rapidly builds NLP models that continuously improve
    Sector: UCL Tech Fund
    Status: Early Stage
  • Developing a new type of all silicon non-volatile memory
    Sector: UCL Tech Fund
    Status: Early Stage
  • Vertically integrated, clinical stage gene therapy company
    Sector: UCL Tech Fund
    Status: Nasdaq IPO
  • Immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer
    Sector: UCL Tech Fund
    Status: Early Stage
  • AI powered platform that unifies large datasets and automatically optimises sales performance for marketplace sellers
    Sector: UCL Tech Fund
    Status: Early Stage
  • Builds a new era of cloud connected endoscopy
    Sector: UCL Tech Fund
    Status: Early Stage
  • Orchard Therapeutics
    Biotechnology company bringing transformative gene therapies to patients with serious and life-threatening orphan diseases
    Sector: UCL Tech Fund
    Status: Nasdaq IPO
  • Panangium Therapeutics
    Biologic for retinal disease targeting a novel alternative pathway to VEGF
    Sector: UCL Tech Fund
    Status: Early Stage
  • Using disruptive theory to unlock the power of quantum computing
    Sector: UCL Tech Fund
    Status: Early Stage
  • Quell Therapeutics
    Cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions
    Sector: UCL Tech Fund
    Status: Growth
  • EdTech platform connecting tutors in the developing countries to students in developed economies
    Sector: UCL Tech Fund
    Status: Early Stage

Let’s talk